Novo Nordisk's (NOVOB.DK) shares dip about 16% due to the company lowering its full-year 2025 sales and operating profit outlook. Previously, investors had higher expectations for Novo Nordisk’s growth rates, but the updated guidance now forecasts sales growth in the 8–14% range for the year, which is below earlier projections (13-21%).
Today’s moves are largely due to weaker-than-expected Wegovy sales in the U.S. obesity market. The updated sales outlook specifically cites reduced growth expectations for Wegovy in the U.S., as well as slower-than-expected market expansion and stronger competition, particularly from Eli Lilly's rival drug Zepbound.
NOVOB shares are back at multi-year lows after cutting forecast. Source: xStation
Chart of the Day: Copper experiences its largest single-day decline since April 2025 (19.11.2026)
Economic Calendar: Trump-Xi Jinping-Putin summit ongoing, time for Walmart results (19.11.2026)
Morning Wrap: Time for the largest stock market debut in history (19.11.2026)
📉Daily Summary: Hawkish Fed and fading optimism around Nvidia hit markets. Gold near 3700